Tyrx gets FDA OK for advanced antibacterial pacemaker envelope

07/10/2013 | Xconomy

Tyrx has gained FDA clearance for a second-generation version of its AigisRx Antibacterial Envelope, designed to protect patients receiving pacemakers and other implantable heart devices from infection. The drug-device combination discharges two antibiotics within seven to 10 days and completely dissolves in the body in about 90 days, CEO Bob White said.

View Full Article in:

Xconomy

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel
Cardinal Health
Columbus, OH
Regulatory Affairs Specialist
Stryker
Mahwah, NJ
Sr. Principal OptoMechanical Engineer - 14000008M2
Abbott
San Jose, CA
Sr. Principal Electrical Engineer - 14000008LR
Abbott
San Jose, CA
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA